The Motley Fool

GlaxoSmithKline teams up with Sanofi for a Covid-19 vaccine. Are its shares worth considering?

Image source: Getty Images

GlaxoSmithKline (LSE: GSK) has teamed up with French pharmaceuticals company Sanofi to develop a vaccine for Covid-19. It’s good news for everyone, but will it be good news for the GlaxoSmithKline share price?

If there is one business activity that public opinion doesn’t like right now, it’s profiteering. Happily, this is not what GlaxoSmithKlin is doing.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

I think GlaxoSmithKline shares look tempting. Not specifically because GSK may help us defeat the virus, but because of what this announcement tells us about the company.

CEO Emma Walmsley has said the company won’t profit from any resulting vaccine during the pandemic. Instead it would use the revenue to fund a ramp-up in manufacturing.

This tells us the company is well placed for the world that will emerge once this crisis is finally over.

The deal

The arrangement entails combining the Sanofi’s DNA technology, which it uses to manufacture flu vaccines, with GSK’s expertise in adjuvant technology. This technology leads to a much stronger immune system reaction, creating more antibodies.

The adjuvant technology means a much lower dosage is required for a vaccine to be effective. As a result, vaccine production can be increased more rapidly.

It is extremely unusual for pharmaceutical companies to collaborate in this way. Walmsley called it “unprecedented“. She also referred to the remarkable speed with which the two companies plan to mass produce a vaccine. They expect the vaccine to be available in the second half of next year. It normally takes many years, even as long as a decade, to be able to mass produce a new vaccine.

That’s modern technology for you. If the Covid-19 pandemic had occurred a few years ago, there would have been no hope of developing a vaccine so fast.

Post Covid-19

I believe that once this crisis is finally at an end, the world will seem like a different place with very different priorities.

There will also be much greater awareness of the dangers from disease. Covid-19 is the third major coronavirus this century. The pressures created by climate change and over-population is some regions means there will probably be more.

Furthermore, with antibiotics losing their effectiveness, I expect to see renewed efforts to develop new antibiotics. GlaxoSmithKline is proving that its outstanding expertise will be invaluable in this new era.

Foolish bottom line

Glaxo’s share price has fallen around 14% from this year’s peak price. In general, I think the markets are underestimating the long-term economic effects of this crisis. GlaxoSmithKline, however, is one of the few companies that I think is well poised for the post Covid-19 era. Recent falls in the share price push its forward price-to-earnings ratio down to around 13. At the current share price, forecast dividends are 5.3%. However, I don’t think the share price is reflective of this upside potential.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Michael Baxter has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Where to invest £1,000 right now

Renowned stock-picker Mark Rogers and his select team of expert analysts at The Motley Fool UK have just revealed 6 "Best Buy" shares that they believe UK investors should consider buying NOW.

So if you’re looking for more top stock ideas to try and best position your portfolio in this market, then I have some good news for your today -- because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.